An interventional study of Specimen extraction through a 10 mm trocar and Specimen extraction through a 12 mm trocar in Appendicitis Acute, sponsored by Sezgin Topuz. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Sezgin Topuz · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies in Appendicitis with a site in Turkey — 10 open to participants now, 12 under way, none of them phase 3. Appendicitis · Turkey.
Among the 45 studies in Appendicitis with a site in Turkey, this one is the 4th largest by planned enrollment of the 25 interventional ones that give a count, is one of 9 that started in 2026, is one of 23 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 45th registered.
421 studies on the registry are indexed under Appendicitis; 67 are open to participants now.
Browse Appendicitis studies →10 of the 45 studies in Appendicitis with a site in Turkey are open now. Recruiting first, the newest first:
Ahmet Burak Doğan, MD · Sites in Turkey
Ages 5–17
Bursa Yuksek Ihtisas Training and Research Hospital · Sites in Turkey
Ages 18–90 · Healthy volunteers
Haydarpasa Numune Training and Research Hospital · Sites in Turkey
Ages 18–65
Ankara Etlik City Hospital · Sites in Turkey
Ages 6–18
Ahmet Burak Doğan, MD · Sites in Turkey
Ages 5–18
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 39 Appendicitis studies recruiting now, 18 (46%) set no upper age limit and 19 (49%) stop at 75 or younger; 23 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 116 across 254 interventional studies indexed under Appendicitis.
Median enrollment 100 across the 25 interventional studies, 142 across the 20 observational. Of the 30 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 45 have an industry lead sponsor. The 10 most frequent:
Sezgin Topuz is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Sezgin Topuz has 1 study filed under Appendicitis — fewer than ten, so there is no comparison to draw.
7 of the studies in Appendicitis with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07824908YUNUS YÜKSELEffect Of Specimen Extraction Site And Local Anesthesia On Postoperative Pain In Laparoscopic Appendectomy | 2026-12-01 |
| NCT07937514Sezgin TopuzSpecimen Integrity in Laparoscopic Appendectomy | 2027-01-01 |
| NCT07926165Haydarpasa Numune Training and Research HospitalSystemic and Tissue Inflammatory Biomarkers in Acute Appendicitis | 2027-01-12 |
| NCT07496723Sanliurfa Education and Research HospitalComparison of Diagnostic Methods in Patients Operated for Suspected Appendicitis | 2027-01-31 |
| NCT07643285Ahmet Burak Doğan, MDFeasibility and Safety of a Pediatric ERAS Protocol for Laparoscopic Appendectomy | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 45 studies in Appendicitis with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether the size of the port (trocar) used to remove the appendix during laparoscopic appendectomy affects whether the appendix is removed intact. The study includes adults (18 years and older) who undergo laparoscopic surgery for acute appendicitis.
The main question it aims to answer is:
- Does removing the appendix through a 12 mm trocar, compared with a 10 mm trocar, reduce damage (tearing or fragmentation) to the removed appendix?
Keeping the appendix intact is important because cancer is sometimes found unexpectedly in removed appendices, and a damaged specimen can make the pathology assessment and further treatment decisions difficult.
Researchers will also compare the two groups for operation time, length of hospital stay, pain after surgery, wound and abdominal infections, bleeding, and hernia at the port site.
Participants will:
Background and rationale:
Laparoscopic appendectomy, first described by Semm in 1983, has become the standard treatment for acute appendicitis in adults. Its proven advantages include lower wound infection rates, faster recovery, and shorter hospital stay. One of the main benefits of laparoscopic surgery is the use of small incisions; however, small incisions can make specimen extraction difficult and may compromise the integrity of the pathological specimen. Although the appendix is a small organ, it is usually extracted through a 10 mm trocar, which occasionally leads to tearing or fragmentation of the specimen. Malignancies such as neuroendocrine tumors and mucinous neoplasms are found incidentally in appendectomy specimens, and a disrupted specimen may complicate pathological staging, margin assessment, and decisions about further treatment. To our knowledge, no prospective randomized controlled trial has compared the effect of trocar size on specimen integrity in laparoscopic appendectomy.
Study design:
This is a single-center, prospective, randomized controlled trial conducted at the Department of General Surgery, Kahramanmaraş Sütçü İmam University Faculty of Medicine. After approval by the institutional ethics committee and written informed consent, patients diagnosed with acute appendicitis and scheduled for laparoscopic appendectomy will be randomly allocated in a 1:1 ratio to two groups. Demographic data (age, sex, comorbidities, height, weight, body mass index) will be recorded.
Interventions:
All operations will be performed using a standard laparoscopic technique with 5 mm, 10 mm, and 12 mm trocars. In Group 1, the appendix will be extracted through a 10 mm trocar; in Group 2, it will be extracted through a 12 mm trocar. All other steps of the operation will follow routine practice. Specimens will be evaluated by the pathology department, and integrity will be classified as intact or disrupted.
Sample size:
Sample size was calculated with G*Power 3.1 (Fisher's exact test, two-tailed). Assuming a specimen disruption rate of 15% with a 10 mm trocar (based on pilot data) and 5% with a 12 mm trocar, with alpha = 0.05 and power = 0.80, 150 patients per group (300 in total) are required.
Statistical analysis:
Normality of continuous variables will be assessed with the Shapiro-Wilk test. Categorical variables, including specimen integrity, will be compared with the chi-square or Fisher's exact test. Continuous variables will be compared with the independent samples t-test or the Mann-Whitney U test, as appropriate. A p value \< 0.05 will be considered statistically significant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Laparoscopic appendectomy with extraction of the appendix through a 10 mm trocar.
Procedure: Specimen extraction through a 10 mm trocar
Laparoscopic appendectomy with extraction of the appendix through a 12 mm trocar.
Procedure: Specimen extraction through a 12 mm trocar
During standard laparoscopic appendectomy, the appendix is removed from the abdominal cavity through a 10 mm trocar, which is the routine practice in our clinic.
During standard laparoscopic appendectomy, the appendix is removed from the abdominal cavity through a 12 mm trocar instead of the routinely used 10 mm trocar. All other steps of the operation are identical.
Rate of Disrupted Appendectomy Specimens
Integrity of the extracted appendix as assessed by the pathologist on macroscopic examination, classified as intact or disrupted (torn, fragmented, or perforated during extraction). The proportion of disrupted specimens will be compared between the 10 mm and 12 mm trocar groups
Time frame: At pathological examination, within 14 days after surgery
Operative Time
Time from skin incision to skin closure, in minutes.
Time frame: Intraoperative
Postoperative Pain Score
Pain intensity measured with the Visual Analog Scale (0 = no pain, 10 = worst
Time frame: At 6, 24, and 48 hours after surgery
Length of Hospital Stay
Number of days from surgery to discharge.
Time frame: From surgery to discharge, up to 30 days
Rate of Surgical Site Infection
Description: Superficial or deep incisional infection and intra-abdominal infection (abscess).
Time frame: Within 30 days after surgery
Rate of Postoperative Bleeding
Bleeding from trocar sites or intra-abdominal bleeding requiring intervention.
Time frame: Within 30 days after surgery
Rate of Trocar Site Hernia
Incisional hernia at the specimen extraction trocar site, diagnosed by physical examination.
Time frame: 6 months after surgery
Plan to share: No — De-identified individual participant data underlying the results reported in the publication will be available upon reasonable request.
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Jan 2027, 5 months after the start.
Of 92 non-industry interventional studies with no phase under Appendicitis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 5 months is below that.
Counting every sponsor, half of 94 studies reached it within 19 months; a quarter within 10 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sezgin Topuz